Applied Genetic Technologies logo

AGTC - Applied Genetic Technologies News Story

$4.04 -0.0  -0.2%

Last Trade - 15/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £125.4m
Enterprise Value £94.0m
Revenue £n/a
Position in Universe 4672nd / 6854

AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021

Tue 16th February, 2021 5:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210216:nGNX76TR7b&default-theme=true


GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) --
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
company conducting human clinical trials of adeno-associated virus (AAV)-based
gene therapies for the treatment of rare diseases, today announced that Sue
Washer, President & Chief Executive Officer, will participate at the OIS Gene
Therapy Innovation Showcase, taking place virtually on Thursday, February 18,
2021 from 12:00 PM to 3:00 PM CST.

The event will include a market overview and start-up spotlight, followed by a
panel discussion featuring recognized experts in the field. The panel will
highlight unique perspectives on gene therapy in the eye care sector and
product viability.

Event registration is complimentary. To register, visit:
https://hopin.com/sign_up

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and central nervous
system (CNS) diseases. AGTC is a leader in designing and constructing all
critical gene therapy elements and bringing them together to develop
customized therapies that address real patient needs. AGTC’s most advanced
clinical programs leverage its best-in-class technology platform to
potentially improve vision for patients with an inherited retinal disease.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on
the Company’s industry-leading AAV manufacturing technology and scientific
expertise. AGTC is advancing multiple important pipeline candidates to address
substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR Contacts:
David Carey (IR) or Tom Vickery (PR)
FINN Partners
T: (212) 867-1768 or (646) 871-8482
david.carey@finnpartners.com or tom.vickery@finnpartners.com

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

(https://www.globenewswire.com/NewsRoom/AttachmentNg/542616ce-01ae-469d-b4ff-5285f7e0584e)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.